BiotechTube

mirabegron + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overactive Bladder (OAB)

Conditions

Overactive Bladder (OAB)

Trial Timeline

Jul 19, 2018 → Mar 30, 2020

NCT ID
NCT03572231

About mirabegron + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine

mirabegron + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine is a pre-clinical stage product being developed by Astellas Pharma for Overactive Bladder (OAB). The current trial status is completed. This product is registered under clinical trial identifier NCT03572231. Target conditions include Overactive Bladder (OAB).

What happened to similar drugs?

10 of 20 similar drugs in Overactive Bladder (OAB) were approved

Approved (10) Terminated (1) Active (9)
✅mirabegron + solifenacinAstellas PharmaApproved
✅Mirabegron + PlaceboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
🔄Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
🔄solifenacin succinateAstellas PharmaPhase 3
✅SolifenacinAstellas PharmaApproved
✅Mirabegron + Tolterodine ERAstellas PharmaApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03572231Pre-clinicalCompleted

Competing Products

20 competing products in Overactive Bladder (OAB)

See all competitors
ProductCompanyStageHype Score
mirabegron + solifenacinAstellas PharmaApproved
43
Mirabegron + PlaceboAstellas PharmaApproved
43
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
BetanisAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaApproved
43
SolifenacinAstellas PharmaPhase 2
35
Mirabegron + Tolterodine ERAstellas PharmaApproved
43
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
26
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
warfarin + YM178Astellas PharmaPhase 1
29
Solifenacin succinateAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved
43
Solifenacin succinateAstellas PharmaApproved
43
Mirabegron + PlaceboAstellas PharmaPhase 3
32
SolifenacinAstellas PharmaPre-clinical
26
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
40